Pilot Therapeutics Holdings Inc. develops and manufactures pharmaceutical products for treatment of dysfunctional lipid metabolism. The company offers Airozin for asthma, PLT 1288 for arthritis, PLT 732 for cardiovascular disease and diabetes, and PLT 2753 for allergic rhinitis. Additionally, it provides clinical trials, personnel recruitment, sales and marketing, and raising capital services. Pilot Therapeutics Holdings Inc. was founded in 1998 and is based in the United States.